PD-1/PD-L1在食管鳞癌中的研究进展

doi:10.11904/j.issn.1002-3070.2017.03.012

实用肿瘤学杂志 ›› 2017, Vol. 31 ›› Issue (3): 250-253.doi: 10.11904/j.issn.1002-3070.2017.03.012

PD-1/PD-L1在食管鳞癌中的研究进展

张群¹ 综述，李多杰² 审校

1.蚌埠医学院(蚌埠 233000);
2.蚌埠医学院第一附属医院肿瘤放疗科

收稿日期:2017-01-10 出版日期:2017-06-28 发布日期:2017-07-04
通讯作者: 李多杰,E-mail:liduojie@163.com
作者简介:张群,女,(1991-),硕士研究生,从事肿瘤放射治疗方向的研究
基金资助:
蚌埠医学院2016研究生创新计划项目(Byycx1651)

Research progress of PD-1/PD-L1 in esophageal squamous cells

ZHANG Qun¹,LI Duojie²

1.Bengbu Medical College, Bengbu 233000,China;
2.Department of Radiotherapy,The First Affiliated Hospital of Bengbu Medical College

Received:2017-01-10 Online:2017-06-28 Published:2017-07-04

摘要/Abstract

摘要： 食管癌的发病率和死亡率均较高,也是最难治疗和治愈的恶性肿瘤之一。当前,免疫检查点抑制剂在肿瘤治疗中取得了突破进展,相关研究已成为热点,针对免疫检查点“程序性死亡分子1”(PD-1)及其配体PD-L1抗体的临床研究也正在广泛开展,本文就PD-1/PD-L1在食管鳞癌中的研究进展做一综述。

关键词: PD-1, PD-L1, 食管鳞癌

Abstract: Esophageal cancer morbidity and mortality are high,but it is also the most difficult to treat and cure one of the malignant tumors.At present,immunoinhibitors have made breakthroughs in the treatment of cancer,and related research,Which have become a hot field for the clinical study of immunological checkpoint “procedural death molecule 1”(PD-1)and its ligand PD-L1 antibody.In this paper,we reviewed the progress of PD-1/PD-L1 in esophageal squamous cell carcinoma.

Key words: PD-1, PD-L1, Esophageal squamous cell

中图分类号:

R735.1

张群综述，李多杰审校. PD-1/PD-L1在食管鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(3): 250-253.

ZHANG Qun,LI Duojie. Research progress of PD-1/PD-L1 in esophageal squamous cells[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 250-253.

参考文献

1 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
2 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
3 Cohen DJ.An expert opinion on esophageal cancer therapy[J].Exp Opin Pharmacother,2011,12(2):225-239.
4 Lote H,Cafferkey C,Chau I.PD-1 and PD-L1 blockade in gastrointestinal malignancies.[J].Cancer Treat Rev,2015,41(10):893-903.
5 Lim JS,Sundar R,Chénardpoirier M,et al.Emerging biomarkers for PD-1 pathway cancer therapy[J].Biomark Med,2017,11(1):53-67.
6 Leng C,Li Y,Qin J,et al.Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺T cells[J].Oncol Rep,2015,35(2):699.
7 Yamazaki T,Akiba H,Iwai H,et al.Expression of programmed death 1 ligands by murine T cells and APC[J].J Immunol,2002,169(10):5538-5545.
8 Barber DL,Wherry EJ,Masopust D,et al.Restoring function in exhausted CD8 T cells during chronic viral infection[J].Nature,2006,439(7077):682-687.
9 Song X,Liu J,Lu Y,et al.Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer[J].Oncol Rep,2014,31(3):1191-1198.
10 Azuma T,Yao S,Zhu G,et al.B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells[J].Blood,2008,111(7):3635-3643.
11 Ghiotto M,Gauthier L,Serriari N,et al.PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1[J].Int Immunol,2010,22(8):651-660.
12 Parry RV,Chemnitz JM,Frauwirth KA,et al.CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms[J].Mol Cell Biol,2005,25(11):9543-9553.
13 Patsoukis N,Brown J,Petkova V,et al.Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation[J].Sci Signal,2012,5(230):1755-1762.
14 Ohaegbulam KC,Assal A,Lazar-Molnar E,et al.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med,2015,21(1):24-33.
15 Pauken KE,Wherry EJ,John E.Overcoming T cell exhaustion in infection and cancer[J].Trends Immunol,2015,36(4):265-276.
16 Spranger S,Spaapen RM,Zha Y,et al.Up-regulation of PD-L1,IDO,and Tregs in the melanoma tumor microenvironment is driven by CD8⁺T cells[J].Sci Transl Med,2013,5(200):2418-2419.
17 Akbay EA,Koyama S,Carretero J,et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors[J].Cancer Discov,2013,3(12):1355-1363.
18 Obeid JM,Erdag G,Smolkin ME,et al.PD-L1,PD-L2 and PD-1 expression in metastatic melanoma:Correlation with tumor-infiltrating immune cells and clinical outcome[J].Oncoimmunology,2016,5(11):e1235107.
19 Thompson RH,Dong H,Kwon ED.Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy[J].Clin Cancer Res,2007,13(2 Pt 2):709-715.
20 Kim JW,Nam KH,Ahn SH,et al.Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer[J].Gastric Cancer,2016,19(1):1-11.
21 Feng Z,Xiang-Lei L,Hai-Tao W,et al.Programmed cell death 1 expression in esophageal squamous cell carcinoma and association with clinical characteristics[J].Indian J Cancer,2015,52(Suppl 3):176-178.
22 Chen K,Cheng G,Zhang F,et al.Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma[J].Oncotarget,2016,7(21):30772-30780.
23 Kim R,Keam B,Kwon D,et al.Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma[J].World J Gastroenterology,2016,22(37):8389-8397.
24 Bang YJ,Chung HC,Shankaran V,et al.Relationship between PD-L1 expression and clinical outcomes in patients(Pts)with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab(Pembro;MK-3475)in KEYNOTE-012[C].Chicago:ASCO,2015.
25 Jiang D,Song Q,Wang H,et al.Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma[J].Oncotarget,2017,8(5):8315-8329.
26 Wang X,Teng F,Li K,et al.PD-L1 expression in human cancers and its association with clinical outcomes[J].Onco Targets Ther NLM,2016,9(11):5023-5039.
27 Pyo JS,Kang G,Kim JY.Prognostic role of PD-L1 in malignant solid tumors:a meta-analysis[J].Int J Biol Markers,2016,27(4):422-424.
28 Zheng H,Liu X,Zhang J,et al.Expression of PD-1 on CD4⁺T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer[J].Oncotarget,2016,7(35):56233-56240.
29 黄海涛,张光波,李广斌,等.食管癌患者外周血PD-L1+CD14+HLA-DR-/low细胞的免疫抑制作用及临床意义[C].苏州:全国肿瘤生物治疗学术会议,2013.
30 Bang YJ,Van CE,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
31 Fuchs CS,Tomasek J,Yong CJ,et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial[J].Lancet,2014,383(9911):31-39.
32 Le DT,Bendell JC,Calvo E,et al.Safety and activity of nivolumab monotherapy in advanced and metastatic(A/M)gastric or gastroesophageal junction cancer(GC/GEC):Results from the CheckMate-032 study[J].J Clin Onco,2016,54(1):59-68.
33 Doi T,Pihapaul SA,Jalal SI,et al.Pembrolizumab(MK-3475)for patients(pts)with advanced esophageal carcinoma:Preliminary results from KEYNOTE-028[J].J Clin Oncol,2015,120(1):114-118.

[1]	马悦,陶冀. MSI结直肠癌的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 376-380.
[2]	周士祥，综述，李多杰，审校. 锌离子转运体LIV-1在食管鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 572-576.
[3]	杨留勤, 武莉萍, 赵春霞, 陈利军, 张如楠, 黄海航, 任民柱. RUNX3与OPN在食管鳞癌组织中的表达及其临床意义[J]. 实用肿瘤学杂志, 2010, 24(4): 378-381.
[4]	吴晁;陈同钰;孟凡青;樊祥山. 癌-睾丸抗原NY-ESO-1在食管鳞状细胞癌中的表达及其意义[J]. 实用肿瘤学杂志, 2007, 21(01): 18-20.

PD-1/PD-L1在食管鳞癌中的研究进展

Research progress of PD-1/PD-L1 in esophageal squamous cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价